Brain Health

Phase 3 trial results also indicate that Alzheimer disease clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks.

All patients present opportunities, but patients who might be considered more challenging due to their condition are often the cases where pharmacists might make the greatest difference

Patients may not admit or recognize when they have a brain injury, but pharmacists can be a valuable resource.

Corium’s Adlarity system lowers the likelihood of adverse gastrointestinal (GI) events that are normally associated with the oral medication.

Help patients get regular checkups and show them how to use BP machines and improve adherence.

Suvorexant (Belsomra) is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Although pharmacotherapy is considered for the treatment of insomnia, medication should not be the sole treatment for individuals diagnosed with insomnia.

Using a transgenic mouse model of Alzheimer’s disease, scientists demonstrate a definitive connection with oxidative brain damage.

Prior studies indicate that CPAP treatment can significantly decrease sleepiness and depression while also protecting against high blood pressure.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses the future of ketamine and psychedelic medicines in the treatment of mental health and brain disorders.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, addresses how pharmacists can respond to questions patients may ask them about ketamine and other psychedelic treatments.

Although the researchers were able to find an association between a heart attack and faster cognitive decline, the findings did not establish that a heart attack directly causes cognitive decline.

Individuals who smoke cigarettes regularly and are yet otherwise healthy, without high blood pressure or type 2 diabetes, are still risking their brain health, new study results show.

Even after taking cardiovascular risks or vascular brain injury into account, the association remained, study results show.

Armodafinil and modafinil have wake-promoting actions similar to sympathomimetic agents.

New study results show that of those who tested or were presumed positive for SARS-CoV-2, 44% developed neurological symptoms.

The results of a new analysis show that just 12 to 14 doses of stimulation for the body and mind may be all that is needed to boost brain function.

Tau protein, plaque, and brain waves maybe the solutions to treating the progressive condition.

New study results may help improve automated methods for detecting these spindles and correlating them with brain function, investigators say.

Daridorexant (Quviviq) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

New study results suggest that severe depression and sexual dysfunction, in particular, can affect a woman's attention, language, orientation, recall, registration, and visuospatial skills.

Analysis examines the impacted of expected trends in exposure to high blood sugar, low education levels, obesity, and smoking.

Daridorexant (Quviviq, Idorsia Pharmaceuticals) is indicated for adults who experience difficulties with sleep onset and/or sleep maintenance.

New study results show that though men are more likely to have heart conditions, the impact on their memory and thinking skills is lower.

There were no instances of participants withdrawing from the study due to an adverse event caused by psilocybin in the treatment of mental health conditions.

When using a therapy to clear the senescent cells, disease progression and cell death were stopped, according to the study.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses the problems with approaching public health issues, such as mental health and substance use disorders, with an industrialized approach to problem solving.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which environments each psychedelic medicine is likely to be administered.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.